Follicular Lymphoma: Refining Prognostic Models and Impact of Pod-24 in Clinical Outcomes
Follicular lymphoma (FL) is the most common indolent lymphoma, accounting for 20%-25% of all non –Hodgkin's lymphomas (NHLs). It is a malignancy with variable biologic presentation and heterogeneous clinical outcomes. Several models incorporating clinical laboratory variables and molecular biomarkers are able to predict its prognosis, allowing to stratify patients into different risk groups. However, these prognostic scores should not be used to indicate first-line treatment or risk-adapted therapeutic recommendations.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Daniel Silva Nogueira, Lu ís Alberto de Pádua Covas Lage, Hebert Fabrício Culler, Juliana Pereira Tags: Review Article Source Type: research
More News: Cancer & Oncology | Hematology | Laboratory Medicine | Leukemia | Lymphoma | Molecular Biology | Myeloma